166 related articles for article (PubMed ID: 30714270)
1. Prodrome in relapsing-remitting and primary progressive multiple sclerosis.
Wijnands JMA; Zhu F; Kingwell E; Zhao Y; Evans C; Fisk JD; Marrie RA; Tremlett H
Eur J Neurol; 2019 Jul; 26(7):1032-1036. PubMed ID: 30714270
[TBL] [Abstract][Full Text] [Related]
2. Five years before multiple sclerosis onset: Phenotyping the prodrome.
Wijnands JM; Zhu F; Kingwell E; Zhao Y; Ekuma O; Lu X; Evans C; Fisk JD; Marrie RA; Tremlett H
Mult Scler; 2019 Jul; 25(8):1092-1101. PubMed ID: 29979093
[TBL] [Abstract][Full Text] [Related]
3. Profile of Polish patients with primary progressive multiple sclerosis.
Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A
Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082
[TBL] [Abstract][Full Text] [Related]
4. Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome.
Kantarci OH; Lebrun C; Siva A; Keegan MB; Azevedo CJ; Inglese M; Tintoré M; Newton BD; Durand-Dubief F; Amato MP; De Stefano N; Sormani MP; Pelletier D; Okuda DT
Ann Neurol; 2016 Feb; 79(2):288-94. PubMed ID: 26599831
[TBL] [Abstract][Full Text] [Related]
5. Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study.
Wijnands JMA; Kingwell E; Zhu F; Zhao Y; Högg T; Stadnyk K; Ekuma O; Lu X; Evans C; Fisk JD; Marrie RA; Tremlett H
Lancet Neurol; 2017 Jun; 16(6):445-451. PubMed ID: 28434855
[TBL] [Abstract][Full Text] [Related]
6. Progression rates and sample size estimates for PPMS based on the CLIMB study population.
Raghavan K; Healy BC; Carruthers RL; Chitnis T
Mult Scler; 2015 Feb; 21(2):180-8. PubMed ID: 25070676
[TBL] [Abstract][Full Text] [Related]
7. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O
Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878
[TBL] [Abstract][Full Text] [Related]
8. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
9. Employment and absenteeism in working-age persons with multiple sclerosis.
Salter A; Thomas N; Tyry T; Cutter G; Marrie RA
J Med Econ; 2017 May; 20(5):493-502. PubMed ID: 28035846
[TBL] [Abstract][Full Text] [Related]
10. Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.
Jia X; Madireddy L; Caillier S; Santaniello A; Esposito F; Comi G; Stuve O; Zhou Y; Taylor B; Kilpatrick T; Martinelli-Boneschi F; Cree BAC; Oksenberg JR; Hauser SL; Baranzini SE
Ann Neurol; 2018 Jul; 84(1):51-63. PubMed ID: 29908077
[TBL] [Abstract][Full Text] [Related]
11. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal.
Montalban X; Sastre-Garriga J; Filippi M; Khaleeli Z; Téllez N; Vellinga MM; Tur C; Brochet B; Barkhof F; Rovaris M; Miller DH; Polman CH; Rovira A; Thompson AJ
Mult Scler; 2009 Dec; 15(12):1459-65. PubMed ID: 19995843
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic brain MRI findings in primary progressive multiple sclerosis.
Kremenchutzky M; Lee D; Rice GP; Ebers GC
Mult Scler; 2000 Apr; 6(2):81-5. PubMed ID: 10773852
[TBL] [Abstract][Full Text] [Related]
13. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.
Suhy J; Rooney WD; Goodkin DE; Capizzano AA; Soher BJ; Maudsley AA; Waubant E; Andersson PB; Weiner MW
Mult Scler; 2000 Jun; 6(3):148-55. PubMed ID: 10871825
[TBL] [Abstract][Full Text] [Related]
14. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
[TBL] [Abstract][Full Text] [Related]
15. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
Brettschneider J; Jaskowski TD; Tumani H; Abdul S; Husebye D; Seraj H; Hill HR; Fire E; Spector L; Yarden J; Dotan N; Rose JW
J Neuroimmunol; 2009 Dec; 217(1-2):95-101. PubMed ID: 19879655
[TBL] [Abstract][Full Text] [Related]
16. Different cognitive profiles of Brazilian patients with relapsing-remitting and primary progressive multiple sclerosis.
Rodrigues DN; Paes RA; Vasconcelos CC; Landeira-Fernandez J; Alvarenga MP
Arq Neuropsiquiatr; 2011 Aug; 69(4):590-5. PubMed ID: 21877025
[TBL] [Abstract][Full Text] [Related]
17. Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.
Kerbrat A; Hamonic S; Leray E; Tron I; Edan G; Yaouanq J;
Eur J Neurol; 2015 Mar; 22(3):507-e35. PubMed ID: 25515927
[TBL] [Abstract][Full Text] [Related]
18. Age-dependent variation of female preponderance across different phenotypes of multiple sclerosis: A retrospective cross-sectional study.
Miclea A; Salmen A; Zoehner G; Diem L; Kamm CP; Chaloulos-Iakovidis P; Miclea M; Briner M; Kilidireas K; Stefanis L; Chan A; Evangelopoulos ME; Hoepner R
CNS Neurosci Ther; 2019 Apr; 25(4):527-531. PubMed ID: 30411534
[TBL] [Abstract][Full Text] [Related]
19. Mining healthcare data for markers of the multiple sclerosis prodrome.
Högg T; Wijnands JMA; Kingwell E; Zhu F; Lu X; Evans C; Fisk JD; Marrie RA; Zhao Y; Tremlett H
Mult Scler Relat Disord; 2018 Oct; 25():232-240. PubMed ID: 30121490
[TBL] [Abstract][Full Text] [Related]
20. Global transcriptome profiling of mild relapsing-remitting versus primary progressive multiple sclerosis.
Koch MW; Ilnytskyy Y; Golubov A; Metz LM; Yong VW; Kovalchuk O
Eur J Neurol; 2018 Apr; 25(4):651-658. PubMed ID: 29316044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
